// App-Quantinova.ai

[SAT0004] : INCREASED LEVELS OF THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR - TAFI CORRELATE WITH COMPLEMENT ACTIVATION IN PATIENTS WITH THE ANTIPHOSPHOLIPID SYNDROME

Researchers

Presenter

  • A. Antovic

Principal Investigators

  • A. Vikerfors

  • B. Woodhams

  • M. Adam

  • E. Svenungsson

Medical Centers

  • Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet S-171 76, Stockholm, Sweden

  • Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet S-171 76, Stockholm, Sweden

  • Diagnostica Stago, Gennevilliers, France

Locations

  • France

  • Sweden

Companies

  • Haemacon Limited

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Antiphospholipid syndrome

  • Venous thrombosis

  • Lupus

Biomarkers

  • Complement 3

  • Complement Component 5a

Drug/Treatment

  • Evithrom

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved